TCMD
Tactile Systems Technology, Inc.
$24.90
-0.73
(-2.85%)
Mkt Cap
561.65M
Volume
168,019
52W Range
9.415-37.77
Sector
Healthcare
Beta
0.82
EPS (TTM)
0.90
P/E Ratio
27.67
Revenue (TTM)
343.52M
Rev Growth (5Y)
+12.0%
EPS Growth (5Y)
+18.5%
AlphaVal · Fair Value
$21.17
Overvalued · Moderate
17.6% above fair value
AlphaQuality · Grade · Gated
F
Stable Earnings Power
30.0 / 100 pillar composite (overridden)
Company Description
Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 329.52M | 292.98M | 274.42M | 246.78M | 208.06M | 187.13M | 189.49M | 143.75M | 109.28M | 84.54M | 62.87M | 47.74M |
| Net Income | 19.09M | 16.96M | 28.52M | (17.87M) | (11.81M) | (620,000) | 10.97M | 6.62M | 5.86M | 2.88M | 1.39M | 2.07M |
| EPS | 0.83 | 0.71 | 1.24 | -0.89 | -0.60 | -0.03 | 0.58 | 0.34 | 0.34 | 0.18 | -0.03 | 0.01 |
| Free Cash Flow | 40.43M | 38.15M | 33.37M | 3.29M | 276,000 | 503,000 | (3.48M) | (539,000) | 372,000 | 6.20M | N/A | N/A |
| FCF / Share | 1.77 | 1.60 | 1.46 | 0.16 | 0.01 | 0.03 | -0.18 | -0.03 | 0.02 | 0.70 | N/A | N/A |
| Operating CF | 42.81M | 40.66M | 35.85M | 5.21M | 2.63M | 2.79M | 2.51M | 9.01M | 4.19M | 7.03M | N/A | N/A |
| Total Assets | 273.94M | 297.92M | 281.44M | 255.00M | 244.27M | 174.09M | 151.75M | 107.07M | 88.45M | 73.94M | N/A | N/A |
| Total Debt | 15.96M | 45.11M | 50.38M | 72.23M | 80.61M | 21.39M | 16.59M | 5,000 | 17,000 | 67,000 | N/A | N/A |
| Cash & Equiv | 83.45M | 94.37M | 61.03M | 21.93M | 28.23M | 47.85M | 22.77M | 20.10M | 23.97M | 30.70M | N/A | N/A |
| Book Value | 218.90M | 216.60M | 193.64M | 121.40M | 128.23M | 124.75M | 112.59M | 89.27M | 72.79M | 59.64M | N/A | N/A |
| Return on Equity | 0.09 | 0.08 | 0.15 | -0.15 | -0.09 | -0.00 | 0.10 | 0.07 | 0.08 | 0.05 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 75.27M | 103.59M | 85.75M | 78.91M | 61.27M | 85.58M | 73.09M | 73.22M | 61.09M | 77.65M | 69.59M | 68.34M |
| Net Income | (1.76M) | 10.63M | 8.21M | 3.22M | (2.97M) | 9.72M | 5.16M | 4.30M | (2.21M) | 8.20M | 22.30M | (100,000) |
| EPS | -0.08 | 0.47 | 0.37 | 0.14 | -0.13 | 0.40 | 0.21 | 0.18 | -0.09 | 0.35 | 0.95 | -0.00 |
| Free Cash Flow | (1.17M) | 16.79M | 9.22M | 14.39M | 10,000 | 15.84M | 9.28M | 12.61M | 422,000 | 17.41M | 3.70M | 13.06M |
| FCF / Share | -0.05 | 0.75 | 0.40 | 0.62 | 0.00 | 0.66 | 0.39 | 0.53 | 0.02 | 0.75 | 0.16 | 0.56 |
| Operating CF | (339,000) | 17.30M | 10.34M | 14.76M | 417,000 | 16.33M | 10.26M | 13.14M | 924,000 | 18.35M | 4.10M | 13.91M |
| Total Assets | 272.12M | 273.94M | 259.18M | 273.05M | 280.24M | 297.92M | 287.72M | 278.78M | 272.04M | 281.44M | 293.31M | 273.73M |
| Total Debt | 15.17M | 15.96M | 16.73M | 42.17M | 43.65M | 45.11M | 46.56M | 47.59M | 48.99M | 50.38M | 68.19M | 69.54M |
| Cash & Equiv | 74.99M | 83.45M | 65.97M | 81.53M | 83.62M | 94.37M | 82.15M | 73.62M | 60.71M | 61.03M | 66.04M | 63.21M |
| Book Value | 217.87M | 218.90M | 204.95M | 194.93M | 205.63M | 216.60M | 207.90M | 200.68M | 193.47M | 193.64M | 182.83M | 158.76M |
| Return on Equity | -0.01 | 0.05 | 0.04 | 0.02 | -0.01 | 0.04 | 0.02 | 0.02 | -0.01 | 0.04 | 0.12 | -0.00 |
TCMD News
Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference
Should Value Investors Buy Tactile Systems Technology (TCMD) Stock?
Tactile Systems Technology, Inc. (TCMD) Q1 2026 Earnings Call Transcript
Tactile Systems Technology (TCMD) Reports Q1 Loss, Tops Revenue Estimates
Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results
Tactile Systems Technology (NASDAQ:TCMD) Stock Passes Below 50 Day Moving Average – Should You Sell?
Tactile Medical to Release First Quarter of Fiscal Year 2026 Financial Results on May 4, 2026
Tactile Systems Technology, Inc. (NASDAQ:TCMD) Receives Consensus Rating of “Moderate Buy” from Brokerages
Should Value Investors Buy Tactile Systems Technology (TCMD) Stock?
3 Medical Instrument Stocks Tapping GenAI to Navigate Industry Woes